Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Elizabeth Holmes’ partner reportedly fundraising for new blood-testing startup

From TechCrunch

By Anthony Ha

May 10, 2025

Elizabeth Holmes’ partner reportedly fundraising for new blood-testing startup

Elizabeth Holmes’ partner reportedly fundraising for new blood-testing startup

Billy Evans, partner of Theranos founder Elizabeth Holmes, is working on a new startup that seeks to deliver “human health optimization” through blood testing, according to The New York Times.

The Times reportedly spoke to two investors pitched on the startup, called Haemanthus, and also viewed some of Haemanthus’ marketing materials.

In those materials, the company says it has developed a machine that uses lasers to analyze blood, saliva, and urine samples to detect cancer and infections. It reportedly plans to start with pet health before expanding to humans, and it seeks to raise more than $50 million.

The pitch echoes that for Theranos, which promised to conduct a variety of medical tests on tiny amounts of blood drawn from pricked fingers. In 2022, Holmes (with whom Evans has two children) was sentenced to 11 years in priso for defrauding investors, though she said in a recent interview that she remains “completely committed to my dream of making affordable healthcare solutions available to everyone.”

Early Facebook investor Jim Breyer told The Times that his team was asked to invest but declined “for many of the same reasons we passed twice on Theranos.”

View original article on techcrunch.com

Most Recent

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow is targeting a new class of endpoint risks created by the rapid adoption of AI agents and developer tools inside enterprises.

Jul 22, 2026

Similar Posts

Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

India-based Miraqules developed a nanotechnology that mimics blood clotting proteins to quickly stop heavy bleeding.

Oct 27, 2025

The fallout after Bolt’s aggressive fundraising attempt has been wild

The fallout after Bolt’s aggressive fundraising attempt has been wild

This past week was a wild one in the world of fintech as Bolt surprised the industry with a leaked term sheet that revealed it is trying to raise $200 million in equity and an unusual, additional $250 million in “marketing credits.” As part of this deal, Bolt wanted a $14 billion valuation bolstered by an aggressive pay-to-play type cramdown that would try and force its existing investors to cough up more cash, too, or essentially lose their stakes to a 1 cent per share buyout. The industry re

Aug 24, 2024

Whoop opens blood-testing service to what it says is a 350,000-person waitlist

Whoop opens blood-testing service to what it says is a 350,000-person waitlist

Whoop Advanced Labs marries subscription blood tests with its fitness device monitoring for tech-powered wellness advice.

Sep 30, 2025

Sprinter Health raises $55M to expand its at-home healthcare service

Sprinter Health raises $55M to expand its at-home healthcare service

The Series B was led by General Catalyst, with Andreessen Horowitz, Regents of the University of California, Google Ventures, and Accel also investing.

May 15, 2025

Most Recent

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow is targeting a new class of endpoint risks created by the rapid adoption of AI agents and developer tools inside enterprises.

Jul 22, 2026

Similar Posts

Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

India-based Miraqules developed a nanotechnology that mimics blood clotting proteins to quickly stop heavy bleeding.

Oct 27, 2025

The fallout after Bolt’s aggressive fundraising attempt has been wild

The fallout after Bolt’s aggressive fundraising attempt has been wild

This past week was a wild one in the world of fintech as Bolt surprised the industry with a leaked term sheet that revealed it is trying to raise $200 million in equity and an unusual, additional $250 million in “marketing credits.” As part of this deal, Bolt wanted a $14 billion valuation bolstered by an aggressive pay-to-play type cramdown that would try and force its existing investors to cough up more cash, too, or essentially lose their stakes to a 1 cent per share buyout. The industry re

Aug 24, 2024

Whoop opens blood-testing service to what it says is a 350,000-person waitlist

Whoop opens blood-testing service to what it says is a 350,000-person waitlist

Whoop Advanced Labs marries subscription blood tests with its fitness device monitoring for tech-powered wellness advice.

Sep 30, 2025

Sprinter Health raises $55M to expand its at-home healthcare service

Sprinter Health raises $55M to expand its at-home healthcare service

The Series B was led by General Catalyst, with Andreessen Horowitz, Regents of the University of California, Google Ventures, and Accel also investing.

May 15, 2025